Literature DB >> 26696781

Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve.

Po-Ming Wang1, Na-Na Chung1, Wei-Chung Hsu2, Feng-Ling Chang1, Chin-Jyh Jang1, Marta Scorsetti3.   

Abstract

AIM: To discuss current dosage for stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC) patients and suggest alternative treatment strategies according to liver segmentation as defined by the Couinaud classification.
BACKGROUND: SBRT is a safe and effective alternative treatment for HCC patients who are unable to undergo liver ablation/resection. However, the SBRT fractionation schemes and treatment planning strategies are not well established.
MATERIALS AND METHODS: In this article, the latest developments and key findings from research studies exploring the efficacy of SBRT fractionation schemes for treatment of HCC are reviewed. Patients' characteristics, fractionation schemes, treatment outcomes and toxicities were compiled. Special attention was focused on SBRT fractionation approaches that take into consideration liver segmentation according to the Couinaud classification and functional hepatic reserve based on Child-Pugh (CP) liver cirrhosis classification.
RESULTS: The most common SBRT fractionation schemes for HCC were 3 × 10-20 Gy, 4-6 × 8-10 Gy, and 10 × 5-5.5 Gy. Based on previous SBRT studies, and in consideration of tumor size and CP classification, we proposed 3 × 15-25 Gy for patients with tumor size <3 cm and adequate liver reserve (CP-A score 5), 5 × 10-12 Gy for patients with tumor sizes between 3 and 5 cm or inadequate liver reserve (CP-A score 6), and 10 × 5-5.5 Gy for patients with tumor size >5 cm or CP-B score.
CONCLUSIONS: Treatment schemes in SBRT for HCC vary according to liver segmentation and functional hepatic reserve. Further prospective studies may be necessary to identify the optimal dose of SBRT for HCC.

Entities:  

Keywords:  Hepatitis B virus; Hepatocellular carcinoma; Segment; Stereotactic body radiation therapy

Year:  2015        PMID: 26696781      PMCID: PMC4661347          DOI: 10.1016/j.rpor.2015.03.005

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  44 in total

1.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.

Authors:  L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion.

Authors:  Atsushi Kudo; Shinji Tanaka; Daisuke Ban; Satoshi Matsumura; Takumi Irie; Noriaki Nakamura; Shigeki Arii
Journal:  Am J Surg       Date:  2013-10-08       Impact factor: 2.565

3.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

4.  Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.

Authors:  Dong Jin Suh; Soon Ho Um; Eva Herrmann; Ju-Hyun Kim; Young Sok Lee; Heon Ju Lee; Myung Seok Lee; Youn-Jae Lee; Weibin Bao; Patricia Lopez; Han Chu Lee; Claudio Avila; Stefan Zeuzem
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

5.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases.

Authors:  Joern Wulf; Matthias Guckenberger; Ulrich Haedinger; Ulrich Oppitz; Gerd Mueller; Kurt Baier; Michael Flentje
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

6.  Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments.

Authors:  P-M Wang; W-C Hsu; N-N Chung; F-L Chang; A Fogliata; L Cozzi
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

Review 7.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

8.  Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.

Authors:  Wei-Chung Hsu; Sue-Ching Chan; Lai-Lei Ting; Na-Na Chung; Po-Ming Wang; Kung-Shih Ying; Jeng-Shiann Shin; Che-Jen Chao; Gau-De Lin
Journal:  Jpn J Clin Oncol       Date:  2006-02       Impact factor: 3.019

9.  Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients.

Authors:  Po-Ming Wang; Wei-Chung Hsu; Na-Na Chung; Feng-Ling Chang; Chin-Jyh Jang; Antonella Fogliata; Marta Scorsetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2014-01-10       Impact factor: 3.481

10.  Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.

Authors:  Dong Hyun Sinn; Geum-Youn Gwak; Juhee Cho; Seung Woon Paik; Byung Chul Yoo
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

View more
  10 in total

1.  Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.

Authors:  M Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-23

2.  Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage.

Authors:  Hiroshi Doi; Norihisa Masai; Kenji Uemoto; Osamu Suzuki; Hiroya Shiomi; Daisaku Tatsumi; Ryoong-Jin Oh
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

3.  Other non-surgical treatments for liver cancer.

Authors:  Paul Revel-Mouroz; Philippe Otal; Marion Jaffro; Antoine Petermann; Olivier Meyrignac; Pierre Rabinel; Fatima-Zohra Mokrane
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-14

4.  Practical utility of liver segmentation methods in clinical surgeries and interventions.

Authors:  Mohammed Yusuf Ansari; Alhusain Abdalla; Mohammed Yaqoob Ansari; Mohammed Ishaq Ansari; Byanne Malluhi; Snigdha Mohanty; Subhashree Mishra; Sudhansu Sekhar Singh; Julien Abinahed; Abdulla Al-Ansari; Shidin Balakrishnan; Sarada Prasad Dakua
Journal:  BMC Med Imaging       Date:  2022-05-24       Impact factor: 2.795

5.  Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.

Authors:  Takashi Iizumi; Toshiyuki Okumura; Yuta Sekino; Hiroaki Takahashi; Yu-Lun Tsai; Daichi Takizawa; Toshiki Ishida; Yuichi Hiroshima; Masatoshi Nakamura; Shosei Shimizu; Takashi Saito; Haruko Numajiri; Masashi Mizumoto; Kei Nakai; Hideyuki Sakurai
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

6.  Glibenclamide, a diabetic drug, prevents acute radiation induced liver injury of mice via up-regulating intracellular ROS and subsequently activating Akt-NF-κB pathway.

Authors:  Hu Liu; Shichao Wang; Zhao Wu; Ziyun Huang; Wei You Chen; Yanyong Yang; Jianguo Cui; Cong Liu; Hainan Zhao; Jiaming Guo; Pei Zhang; Fu Gao; Bailong Li; Jianming Cai
Journal:  Oncotarget       Date:  2017-06-20

7.  Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.

Authors:  Dominik Bettinger; Renan Spode; Nicolas Glaser; Nico Buettner; Tobias Boettler; Christoph Neumann-Haefelin; Thomas Baptist Brunner; Eleni Gkika; Lars Maruschke; Robert Thimme; Michael Schultheiss
Journal:  BMC Gastroenterol       Date:  2017-08-10       Impact factor: 3.067

8.  Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study.

Authors:  Andre Tsin Chih Chen; Fabio Payão; Aline Lopes Chagas; Regiane Saraiva De Souza Melo Alencar; Claudia Megumi Tani; Karina Gondim Moutinho da Conceição Vasconcelos; Manoel de Souza Rocha; Heloisa de Andrade Carvalho; Paulo Marcelo Gehm Hoff; Flair José Carrilho
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

9.  Hepatobiliary scintigraphy allows the evaluation of short-term functional toxicity of liver stereotactic body radiotherapy: Results of a pilot study.

Authors:  Berardino De Bari; Thomas Breuneval; Michele Zeverino; Sarah Godin; Letizia Deantonio; Christine Geldhof; Jean Bourhis; Nicklaus Schaefer; Raphaël Moeckli; John Prior; Mahmut Ozsahin
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

Review 10.  Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?

Authors:  Seo Hee Choi; Jinsil Seong
Journal:  Yonsei Med J       Date:  2018-10       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.